CN116396372B - Peptide-loaded nanoparticle and application thereof in treatment of eye infection of pets - Google Patents
Peptide-loaded nanoparticle and application thereof in treatment of eye infection of pets Download PDFInfo
- Publication number
- CN116396372B CN116396372B CN202310135438.XA CN202310135438A CN116396372B CN 116396372 B CN116396372 B CN 116396372B CN 202310135438 A CN202310135438 A CN 202310135438A CN 116396372 B CN116396372 B CN 116396372B
- Authority
- CN
- China
- Prior art keywords
- peptide
- pets
- plga
- cath
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 44
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 19
- 208000001860 Eye Infections Diseases 0.000 title abstract description 5
- 208000011323 eye infectious disease Diseases 0.000 title abstract description 5
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract description 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 239000002539 nanocarrier Substances 0.000 claims description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 5
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 3
- 230000000845 anti-microbial effect Effects 0.000 claims 4
- 239000004599 antimicrobial Substances 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 208000032536 Pseudomonas Infections Diseases 0.000 claims 1
- 206010041925 Staphylococcal infections Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000015339 staphylococcus aureus infection Diseases 0.000 claims 1
- 239000004005 microsphere Substances 0.000 abstract description 35
- 241000270295 Serpentes Species 0.000 abstract description 19
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 14
- 208000035143 Bacterial infection Diseases 0.000 abstract description 4
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 4
- 210000004087 cornea Anatomy 0.000 abstract description 4
- 210000001519 tissue Anatomy 0.000 abstract description 4
- 210000004400 mucous membrane Anatomy 0.000 abstract description 3
- 150000003384 small molecules Chemical class 0.000 abstract description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 7
- 230000007794 irritation Effects 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310135438.XA CN116396372B (en) | 2023-02-18 | 2023-02-18 | Peptide-loaded nanoparticle and application thereof in treatment of eye infection of pets |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310135438.XA CN116396372B (en) | 2023-02-18 | 2023-02-18 | Peptide-loaded nanoparticle and application thereof in treatment of eye infection of pets |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116396372A CN116396372A (en) | 2023-07-07 |
CN116396372B true CN116396372B (en) | 2024-05-24 |
Family
ID=87013063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310135438.XA Active CN116396372B (en) | 2023-02-18 | 2023-02-18 | Peptide-loaded nanoparticle and application thereof in treatment of eye infection of pets |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116396372B (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102311492A (en) * | 2010-07-09 | 2012-01-11 | 中国科学院昆明动物研究所 | Non-natural fully D-type snake venom cathelicidin antibacterial peptide and derivative, preparation method as well as application thereof |
CN102702333A (en) * | 2012-05-29 | 2012-10-03 | 中国药科大学 | Drug-resistant pathogen infection resistant polypeptide and uses thereof |
WO2017176041A1 (en) * | 2016-04-04 | 2017-10-12 | 건국대학교 산학협력단 | Novel antimicrobial peptide isolated from python and method for discovering same |
CN113754738A (en) * | 2021-08-30 | 2021-12-07 | 国家纳米科学中心 | Polypeptide monomer molecule, self-assembly nano material thereof and application |
CN115536738A (en) * | 2022-04-13 | 2022-12-30 | 江苏亢钧生物科技有限公司 | Application of cobra antibacterial peptide OH-CATH30 in treating enteritis of fishes |
CN115536737A (en) * | 2022-04-13 | 2022-12-30 | 江苏亢钧生物科技有限公司 | Application of cobra antibacterial peptide OH-CATH30 in resisting aquatic animal pathogenic bacteria |
CN116333163A (en) * | 2022-09-29 | 2023-06-27 | 国家纳米科学中心 | Recombinant fusion protein and application thereof |
-
2023
- 2023-02-18 CN CN202310135438.XA patent/CN116396372B/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102311492A (en) * | 2010-07-09 | 2012-01-11 | 中国科学院昆明动物研究所 | Non-natural fully D-type snake venom cathelicidin antibacterial peptide and derivative, preparation method as well as application thereof |
CN102702333A (en) * | 2012-05-29 | 2012-10-03 | 中国药科大学 | Drug-resistant pathogen infection resistant polypeptide and uses thereof |
WO2017176041A1 (en) * | 2016-04-04 | 2017-10-12 | 건국대학교 산학협력단 | Novel antimicrobial peptide isolated from python and method for discovering same |
CN113754738A (en) * | 2021-08-30 | 2021-12-07 | 国家纳米科学中心 | Polypeptide monomer molecule, self-assembly nano material thereof and application |
CN115536738A (en) * | 2022-04-13 | 2022-12-30 | 江苏亢钧生物科技有限公司 | Application of cobra antibacterial peptide OH-CATH30 in treating enteritis of fishes |
CN115536737A (en) * | 2022-04-13 | 2022-12-30 | 江苏亢钧生物科技有限公司 | Application of cobra antibacterial peptide OH-CATH30 in resisting aquatic animal pathogenic bacteria |
CN116333163A (en) * | 2022-09-29 | 2023-06-27 | 国家纳米科学中心 | Recombinant fusion protein and application thereof |
Non-Patent Citations (3)
Title |
---|
King cobra peptide OH-CATH30 as a potential candidate drug through clinic drug-resistant isolates;Feng Zhao;《Zoological Research》;20181231;第39卷(第2期);第87-96页 * |
Therapeutic Potential of the Antimicrobial Peptide OH-CATH30 for Antibiotic-Resistant Pseudomonas aeruginosa Keratitis;Sheng-An Li;《Antimicrobial Agents and Chemotherapy》;20140317;第58卷(第6期);第3144–3150页 * |
眼镜王蛇抗菌肽OH-CATH30选择性地调节天然免疫反应抵御细菌感染;李盛安;《第十一届中国生物毒素研究及医药应用年会论文摘要集》;20131017;摘要 * |
Also Published As
Publication number | Publication date |
---|---|
CN116396372A (en) | 2023-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rashki et al. | Chitosan-based nanoparticles against bacterial infections | |
Labib | Overview on zein protein: A promising pharmaceutical excipient in drug delivery systems and tissue engineering | |
Costa et al. | Potential chitosan-coated alginate nanoparticles for ocular delivery of daptomycin | |
Chang et al. | Amphiphilic hydrogels for biomedical applications | |
Cruz et al. | Antimicrobial activity of a new synthetic peptide loaded in polylactic acid or poly (lactic-co-glycolic) acid nanoparticles against Pseudomonas aeruginosa, Escherichia coli O157: H7 and methicillin resistant Staphylococcus aureus (MRSA) | |
Liu et al. | Composite inclusion complexes containing hyaluronic acid/chitosan nanosystems for dual responsive enrofloxacin release | |
Dadashi et al. | Preparation, characterization, and antibacterial effect of doxycycline loaded kefiran nanofibers | |
Xie et al. | Bacterial ghosts for targeting delivery and subsequent responsive release of ciprofloxacin to destruct intracellular bacteria | |
CN110496229B (en) | Nanoparticle-coated antibacterial peptide with slow release property and preparation method thereof | |
Murueva et al. | Development and characterization of ceftriaxone-loaded P3HB-based microparticles for drug delivery | |
Xu et al. | A novel approach of curcumin loaded chitosan/dextran nanocomposite for the management of complicated abdominal wound dehiscence | |
Durán et al. | Microencapsulation of antibiotic rifampicin in poly (3-hydroxybutyrate-co-3-hydroxyvalerate) | |
Yu et al. | A Tanshinone IIA loaded hybrid nanocomposite with enhanced therapeutic effect for otitis media | |
Jafari et al. | pH-sensitive biocompatible chitosan/sepiolite-based cross-linked citric acid magnetic nanocarrier for efficient sunitinib release | |
Ashvini et al. | Clarithromycin-loaded Chitosan Nanoparticles: Preparation, Characterisation and Antibacterial Activity on Streptococcus pneumonia. | |
CN116396372B (en) | Peptide-loaded nanoparticle and application thereof in treatment of eye infection of pets | |
Taebpour et al. | Fabrication and characterization of PLGA polymeric nanoparticles containing Berberine and its cytotoxicity on breast cancer cell (MCF-7) | |
Cheng et al. | Effect of formulation variables on the performance of doxycycline-loaded PLA microsphere | |
Kermanian et al. | Accelerative effects of alginate-chitosan/titanium oxide@ geraniol nanosphere hydrogels on the healing process of wounds infected with Acinetobacter baumannii and Streptococcus pyogenes bacteria | |
Sharma et al. | Formulation and physicochemical evaluation of nanostructured lipid carrier for codelivery of clotrimazole and ciprofloxacin | |
Shrestha et al. | Versatile use of nanosponge in the pharmaceutical arena: a mini-review | |
Lu et al. | Antheraea pernyi silk fibroin nanoparticles for drug delivery | |
Elkheshen et al. | Formulation of ciprofloxacin hydrochloride loaded biodegradable nanoparticles: optimization of the formulation variables | |
Badar et al. | Chitin-based nanomaterials | |
Ryan et al. | The development of a solid lipid nanoparticle (SLN)-based lacticin 3147 hydrogel for the treatment of wound infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Qin Zhihua Inventor after: Jiao Xiaoqian Inventor after: Dong Xufeng Inventor after: Yu Dezheng Inventor after: Hao Zhipeng Inventor after: Zhang Zhongtao Inventor before: Jiao Xiaoqian Inventor before: Dong Xufeng Inventor before: Yu Dezheng Inventor before: Hao Zhipeng Inventor before: Zhang Zhongtao Inventor before: Qin Zhihua |